718 results about "Bowels diseases" patented technology

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.

The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).

The invention discloses a preparation method and application of a targeted delivery system of a metal polyphenol nano system. The invention discloses a targeted delivery system of a metal polyphenol nano system, and a preparation method of the targeted delivery system comprises the following steps: taking the metal polyphenol nano system formed based on epigallocatechin gallate and iron ions as a carrier, and loading fucoxanthin to prepare fucoxanthin nano particles with active oxygen response characteristics; then, after chondroitin sulfate capable of targeting macrophages and (5-carboxyl amyl) triphenyl phosphorus bromide capable of targeting mitochondria are coupled, the fucoxanthin delivery system with the active oxygen response characteristic and the targeting characteristic is further prepared through a double emulsion anti-solvent evaporation method. The system can realize release of fucoxanthin under stimulation of active oxygen, and realizes aggregation of a targeted delivery system in mitochondria of a specific inflammation site. The carrying system can effectively improve or relieve the inflammatory bowel disease, and the raw materials used in the carrying system are low in cost, the preparation conditions are mild, and large-scale production is easy.

The invention discloses lactobacillus rhamnosus 1.0320, a metagen as well as a preparation method and application of the lactobacillus rhamnosus 1.0320 and the metagen, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on April 8, 2018, and the preservation number of the lactobacillus rhamnosus 1.0320 is CGMCC (China General Microbiological Culture Collection Center) NO.15557. The lactobacillus rhamnosus 1.0320 can be used for preparing the lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 and the metagen thereof provided by the invention have the effects of improving the intestinal barrier and relieving the inflammatory bowel disease.

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.

The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and / or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and / or prevention of inflammatory diseases, in particular, inflammatory bowel disease.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses a multi-layer multi-release metagen composition and application thereof in quickly promoting defecation, lubricating intestinal tracts, relieving intestinal problems such as flatulence, stomachache, diarrhea, constipation, irritable bowel syndrome and inflammatory bowel disease, maintaining intestinal flora balance, repairing intestinal tracts, repairing intestinal mucosa health, relieving dyspepsia and improving gastrointestinal functions.

The present invention provides a pharmaceutical composition having an effective dose of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof for treating inflammatory bowel disease. Disclosed is a pharmaceutical composition for treating inflammatory bowel disease, which comprises a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, where the compound or the pharmaceutically acceptable salt thereof is administered to a human at a dose of 50 mg or more per day as an active ingredient, where R represents a hydroxyl group or an isobutoxy group.

The invention discloses an inflammatory bowel disease activity evaluation system based on multi-modal endoscopic feature fusion, and relates to the field of medical information processing. The system comprises a multi-modal data receiving module used for receiving first EUS microarray multi-modal endoscope dynamic sequence data; the image preprocessing module is used for carrying out noise reduction processing and determining a first white light effective observation image and a first ultrasonic effective observation image; the white light surface feature extraction module is used for extracting mucous membrane surface features by using a white light surface feature extraction model to determine mucous membrane features under a first white light endoscope; the ultrasonic transmural feature extraction module is used for performing structure identification and measurement by using an ultrasonic transmural feature extraction model to determine first ultrasonic lower mucous membrane features; and the multi-modal endoscope IBD activity evaluation module is used for determining the IBD activity based on the multi-modal endoscope characteristics by using the multi-modal dynamic endoscope IBD activity evaluation model. Compared with the prior art, the method has the advantages that the limitation of disease assessment based on single-mode and static pictures in the past is broken through, and the accuracy of IBD activity assessment results is improved.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

According to the application disclosed by the invention, the new lactobacillus rhamnosus LR159 is found for the first time, and the strain can be used for effectively treating the inflammatory bowel disease by inhibiting the inflammation level, recovering the barrier function of intestinal mucosa and regulating and improving the intestinal microenvironment. Compared with known lactobacillus rhamnosus, the LR159 strain provided by the invention has better intestinal colonization ability, and can realize more lasting anti-inflammatory and mucous membrane repair effects by breaking through the limitation of pathological microenvironment of the inflammatory bowel disease, thereby enhancing the treatment effect of the inflammatory bowel disease. In conclusion, the lactobacillus rhamnosus LR159 has a great application prospect in preventing and treating the inflammatory bowel disease.

The invention discloses a polymer material, a drug-loaded micelle solution, a drug-loaded micelle composite hydrogel, and a preparation method and application of the drug-loaded micelle composite hydrogel. The polymer material is obtained by reacting oxidized dextran and oleylamine; wherein the oxidized dextran is obtained by oxidizing dextran with the molecular weight of 35000 to 45000; the oxidation degree of the oxidized dextran is 55-70%; the mass ratio of the oxidized dextran to the oleylamine is 1: (1.2-2.0). The polymer material provided by the invention can form a micelle as a carrier to entrap a hydrophobic drug, such as prednisolone. The drug-loaded micelle composite hydrogel provided by the invention can be used for treating inflammatory bowel disease IBD, can avoid damage of an acid environment to a greater extent, and prolongs the administration time.

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

The invention discloses a preparation method of compound lactobacillus fermented asparagus yoghurt, and belongs to the technical field of food biotechnology and microbial fermentation. The lactobacillus fermented asparagus yoghurt is prepared by taking asparagus primary pulp and fresh cow milk as raw materials, and mixing, fermenting and ripening the raw materials by adopting the lactobacillus paracasei JGSLP08 and the lactobacillus pentosus JGS34, and the obtained compound lactobacillus fermented asparagus yoghurt has excellent antioxidant activity and high-dose lactobacillus viable count; meanwhile, the traditional Chinese medicine composition has a remarkable prevention and treatment effect on inflammatory bowel diseases. The lactobacillus fermented asparagus yoghurt can be widely applied to the field of preventing and / or treating inflammatory bowel diseases, in particular to preparation of food for preventing and / or treating inflammatory bowel diseases.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.

The invention provides an apigenin nanoparticle preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing apigenin, dissolving the apigenin in an acetone solution containing a polylactic acid-glycolic acid copolymer, or dissolving the apigenin in an acetone solution containing the polylactic acid-glycolic acid copolymer and Eudragit S100, and uniformly stirring and mixing at room temperature to obtain a mixed solution; dropwise adding the mixed solution into a polyvinyl alcohol solution, carrying out ultrasonic treatment, and removing the solvent to prepare PANPs or PEANPs. The preparation method is simple, and the prepared PANPs and PEANPs are small in particle size and high in encapsulation efficiency, can effectively penetrate through intestinal epithelial barriers and promote internalization of apigenin into cells, have a good slow release characteristic, can remarkably improve the bioavailability of apigenin, and have a good treatment effect on inflammatory bowel diseases. PANPs has a better treatment effect on ulcerative colitis, and PEANPs has a better treatment effect on diffuse colitis.

The invention relates to the technical field of nano-materials, in particular to a monatomic nano-enzyme drug delivery system for IBD treatment and a preparation method and application of the monatomic nano-enzyme drug delivery system. The monatomic nano enzyme delivery system provided by the invention comprises an iron-doped monatomic nano enzyme Fe-SA, curcumin Cur and hyaluronic acid grafted dopamine HAD, the Fe-SA and the Cur form a Fe-SA / Cur compound through a coordination effect, and the surface of the Fe-SA / Cur compound is coated with the HAD. According to the iron-doped monatomic nano-enzyme Fe-SA, Fe atoms in the iron-doped monatomic nano-enzyme Fe-SA are distributed in a graded carbon-based matrix of the Fe-SA in a Fe-N4 co-doping form, and the iron-doped monatomic nano-enzyme Fe-SA has efficient SOD and CAT nano-enzyme activity, and can realize antioxidant self-cascade nano-enzyme reaction, effectively remove active oxygen and improve the pathological environment. According to the preparation method disclosed by the invention, a coordination compound Fe-SA / Cur is constructed by utilizing the iron-doped monatomic nano-enzyme and the curcumin, so that the anti-inflammatory effect is improved, and the characteristic of poor water solubility of the curcumin is effectively improved. According to the invention, HAD is loaded on the outer layer of a coordination compound Fe-SA / Cur to construct an oral monatomic antioxidant cascade nano-enzyme system, high acid resistance and targeted delivery capability are realized by using the remarkable stability and negative charges of HAD, and oral administration is effectively realized. In-vivo and in-vitro experiments show that the monatomic nano-enzyme delivery system provided by the invention can effectively remove intestinal free radicals, improve the intestinal environment, reduce the expression of inflammatory factors, promote the recovery of damaged tissues and effectively treat colitis. The invention provides a new thought and method for biomedical research and drug development of inflammatory bowel diseases.

The invention discloses a microsphere entrapped with probiotics and ginsenoside as well as a preparation method and application of the microsphere, and aims to realize efficient treatment of flora imbalance inflammatory bowel disease (IBD). The microspheres adopt a bi-component synergistic entrapment technology, can stably bear probiotics and ginsenoside, effectively avoid inactivation or degradation of the probiotics and ginsenoside in gastric acid and cholate environments, and ensure directional release and efficient utilization of the probiotics and ginsenoside in intestinal tracts. The microspheres not only provide a protection effect as a delivery carrier, but also construct a'microreactor 'system, and provide a suitable microenvironment for survival of probiotics and conversion of ginsenoside. Probiotics secrete a specific enzyme to promote prototype ginsenoside to be converted into rare ginsenoside with higher activity and stronger solubility while regulating intestinal flora balance and relieving intestinal inflammation, so that the bioavailability and efficacy of the rare ginsenoside are remarkably improved. According to the microsphere system, the technical bottlenecks of the existing treatment means in the aspects of activity maintenance, directional release and conversion utilization are broken through by realizing the synergistic effect of the probiotics and the ginsenoside, and a brand-new strategy and a technical platform are provided for treatment of flora imbalance related diseases such as IBD.

The invention discloses EGCG-myricetin carrier-free nanoparticles based on hydrogen peroxide oxidation crosslinking as well as a preparation method and application of the EGCG-myricetin carrier-free nanoparticles. The preparation method comprises the following steps: mixing amino acid, EGCG and hydrogen peroxide for reaction to prepare a covalent skeleton of an EGCG-amino acid network; and subjecting myricetin and the covalent skeleton of the EGCG-amino acid network to self-assembly so as to obtain the EGCG-myricetin carrier-free nanoparticles based on hydrogen peroxide oxidation crosslinking. According to the EGCG-myricetin carrier-free nano-particles disclosed by the invention, complex molecular design and tedious preparation schemes of a current delivery system and potential harmful effects of excipients are avoided, the prepared carrier-free nano-particles have good loading effect, stability and biological safety, and meanwhile, the EGCG-myricetin carrier-free nano-particles can obviously improve mouse colitis symptoms induced by DSS; technical support is provided for developing carrier-free nano-particles and relieving inflammatory bowel diseases, and the carrier-free nano-particles have huge clinical development prospects.